Back to Rounds
Series C Round
Funding Details
CellCentric is a biotech company focused on advancing inobrodib in multiple myeloma trials. The company aims to develop innovative therapies for hematological malignancies, particularly targeting relapsed or refractory multiple myeloma. This funding round will support the continued development of their lead candidate and expand clinical trials. The investment will also facilitate collaborations with research institutions to enhance their R&D capabilities and accelerate the path to market for their therapies.
Confidence Score
Participating Investors
Pfizer is a global pharmaceutical corporation that engages in the research, development, and manufacturing of healthcare products, including medicines...
Related Tweets
No tweets found for this funding round.